Evidence & policy library
Every pathway is linked to the organizations responsible for the decision.
19 source records
Methodology
Pathway information draws on official regulator, HTA and payer materials. Consult the cited policy for its conditions and effective date, and see Content & use for guidance on applying Atlas to your research.
Matching documents: 33
Market / scopeOfficial evidence recordTypePolicy / reference dateLast checked
Europe
🇬🇧 United KingdomOfficialUK-wide licence, Category 1/2, UK Only, NI transitioneffective 2025-01-01Latest observed: 2025-03-12 / current
🇬🇧 United KingdomOfficialUK-wide licence, Category 1/2, UK Only, NI transitioneffective 2025-01-01Latest observed: 2025-03-12 / current
🇬🇧 United KingdomOfficialnational/IRP routes, timelines, performance, variationsnational published 2025-04-03Latest observed: 2026-04-09 / 2026-07-14 / June 2026 data
🇬🇧 United KingdomOfficialnational/IRP routes, timelines, performance, variationsnational published 2025-04-03Latest observed: 2026-04-09 / 2026-07-14 / June 2026 data
🇬🇧 United KingdomOfficialnational/IRP routes, timelines, performance, variationsnational published 2025-04-03Latest observed: 2026-04-09 / 2026-07-14 / June 2026 data
🇬🇧 United KingdomOfficialInnovation Passport, TDP, cross-system coordination2025-01-30Latest observed: 2026-05-19
🇬🇧 United KingdomOfficialPIM, scientific opinion, duration, pre-licence boundarycurrent scheme under HMR 167CLatest observed: 2026-03-02
🇬🇧 United KingdomOfficialend-to-end, list price, PAS, four nationscurrent pathwayLatest observed: checked live
🇬🇧 United KingdomOfficialvoluntary portfolio scheme, 14.5%, 15% capscheme 2024-01-01 to 2028-12-31Latest observed: scheme updated 2026-06-02; rate published 2025-12-10
🇬🇧 United KingdomOfficialvoluntary portfolio scheme, 14.5%, 15% capscheme 2024-01-01 to 2028-12-31Latest observed: scheme updated 2026-06-02; rate published 2025-12-10
🇬🇧 United KingdomOfficialstatutory 16.5% and VPAG equivalence rationale2026 changesLatest observed: 2026-06-10
🇬🇧 United KingdomOfficialscope, evidence, EQ-5D-5L UK value set and transition, £25k–£35k, severity, HST, recommendations, managed accessPMG36 published 2022-01-31; PMG51 published/effective prospectively 2026-08-27Latest observed: PMG51 2026-08-27
🇬🇧 United KingdomOfficialscope, evidence, EQ-5D-5L UK value set and transition, £25k–£35k, severity, HST, recommendations, managed accessPMG36 published 2022-01-31; PMG51 published/effective prospectively 2026-08-27Latest observed: PMG51 2026-08-27
🇬🇧 United KingdomOfficialscope, evidence, EQ-5D-5L UK value set and transition, £25k–£35k, severity, HST, recommendations, managed accessPMG36 published 2022-01-31; PMG51 published/effective prospectively 2026-08-27Latest observed: PMG51 2026-08-27
🇬🇧 United KingdomOfficial£40m BIT, PAS/CAA, loss-of-exclusivity rapid updatecurrent manualLatest observed: BIT changed 2025-06; manual updated 2026-03-31
🇬🇧 United KingdomOfficial£40m BIT, PAS/CAA, loss-of-exclusivity rapid updatecurrent manualLatest observed: BIT changed 2025-06; manual updated 2026-03-31
🇬🇧 United KingdomOfficiallegal funding duty and usual 3-month availabilitycurrentLatest observed: checked live
🇬🇧 United KingdomOfficiallegal funding duty and usual 3-month availabilitycurrentLatest observed: checked live
🇬🇧 United KingdomOfficialDCA + commercial agreement, up to 5 years, CDF/IMFcurrentLatest observed: checked 2026-08-01
🇬🇧 United KingdomOfficialPAS, CAA, commercial principles, combination therapy; old threshold conflict flaggedframework updated Jan 2025Latest observed: Jan 2025
🇬🇧 United KingdomOfficialBlueteq, CAP price, CDF/IMF provider reimbursementcurrent SOPLatest observed: checked live
🇬🇧 United KingdomOfficialhospital frameworks, high-cost drugs, commissioning, IFRcurrentLatest observed: 2026
🇬🇧 United KingdomOfficialhospital frameworks, high-cost drugs, commissioning, IFRcurrentLatest observed: 2026
🇬🇧 United KingdomOfficialhospital frameworks, high-cost drugs, commissioning, IFRcurrentLatest observed: 2026
🇬🇧 United KingdomOfficialSMC remit, pre-MA submission, 18/22–26 weeks, PASAGcurrent processLatest observed: checked live
🇬🇧 United KingdomOfficialPACE, ultra-orphan, generic/biosimilar, Board decision vs implementationcurrent / 2024 changeLatest observed: checked 2026-08-01
🇬🇧 United KingdomOfficialPACE, ultra-orphan, generic/biosimilar, Board decision vs implementationcurrent / 2024 changeLatest observed: checked 2026-08-01
🇬🇧 United KingdomOfficialPACE, ultra-orphan, generic/biosimilar, Board decision vs implementationcurrent / 2024 changeLatest observed: checked 2026-08-01
🇬🇧 United KingdomOfficialPACE, ultra-orphan, generic/biosimilar, Board decision vs implementationcurrent / 2024 changeLatest observed: checked 2026-08-01
🇬🇧 United KingdomOfficialNICE/AWMSG boundary, Scrutiny Panel, 60 days, IPFR/local formularynew process 2025-01-01Latest observed: current page checked 2026-08-01
🇬🇧 United KingdomOfficialNICE/AWMSG boundary, Scrutiny Panel, 60 days, IPFR/local formularynew process 2025-01-01Latest observed: current page checked 2026-08-01
🇬🇧 United KingdomOfficialendorsement, 4 weeks, 15 weeks, Trust 3+6 months, PASeffective 2022-04-01Latest observed: current circular
🇬🇧 United KingdomOfficialcurrent-system review, £875m context, reform-not-yet-implemented boundary2025-10-02Latest observed: 2025-10-02
For education only — not regulatory, pricing or legal advice.